AMLODIPINE BESYLATE; CELECOXIB
| Brand name | CONSENSI |
|---|---|
| Active ingredient | AMLODIPINE BESYLATE; CELECOXIB |
| Strength | EQ 5MG BASE;200MG |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | May 2018 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 10350171 | June 2038 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.